### Accepted Manuscript

Microwave-assisted parallel synthesis of benzofuran-2-carboxamide derivatives bearing anti-inflammatory, analgesic and antipyretic agents

Yong-Sheng Xie, Deepak Kumar, B.V.D. Vijaykumar, Tarani P. Shrivastava, Bao-Xiang Zhao, Jun-Ying Miao, Kiwan Jang, Dong-Soo Shin

PII:	S0040-4039(14)00368-2
DOI:	http://dx.doi.org/10.1016/j.tetlet.2014.02.116
Reference:	TETL 44303
To appear in:	Tetrahedron Letters
Received Date:	20 December 2013
Revised Date:	22 February 2014
Accepted Date:	27 February 2014



Please cite this article as: Xie, Y-S., Kumar, D., Vijaykumar, B.V.D., Shrivastava, T.P., Zhao, B-X., Miao, J-Y., Jang, K., Shin, D-S., Microwave-assisted parallel synthesis of benzofuran-2-carboxamide derivatives bearing antiinflammatory, analgesic and antipyretic agents, *Tetrahedron Letters* (2014), doi: http://dx.doi.org/10.1016/j.tetlet. 2014.02.116

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Tetrahedron Letters

journal homepage: www.elsevier.com

# Microwave-assisted parallel synthesis of benzofuran-2-carboxamide derivatives bearing anti-inflammatory, analgesic and antipyretic agents

Yong-Sheng Xie<sup>a,b,#</sup>, Deepak Kumar<sup>a,#</sup>, B. V. D. Vijaykumar<sup>a</sup>, Tarani P. Shrivastava<sup>c</sup>, Bao-Xiang Zhao<sup>d</sup>, Jun-Ying Miao<sup>d</sup>, Kiwan Jang<sup>a</sup>, Dong-Soo Shin<sup>a,\*</sup>

<sup>a</sup>Departments of Chemistry and Physics, Changwon National University, Changwon, 641-773, S. Korea <sup>b</sup>College of Chemical and Environmental Engineering, Chongqing Three Gorges University, Chongqing, 404100, P.R. China <sup>c</sup>Department of Pharmacology, School of Pharmacy and Research centre, People's University, Bhopal, 462 037, India <sup>d</sup>Institute of Organic Chemistry and DevelopmentalBiology, Shandong University, Jinan, 250100, China

#### ARTICLE INFO

Received in revised form

Benzofuran-2-carboxamides Microwave-assisted synthesis

Knoevenagel condensation Anti-inflammatory activity Analgesic activity Antipyretic activity

Article history: Received

Accepted Available online

Keywords:

ABSTRACT


A series of benzofuran-2-carboxamides of biological and medicinal significance were synthesized by a microwave-assisted one-pot parallel approach *via O*-alkylation/Knoevenagel condensation. All the compounds were characterized and assayed for their in *vivo* anti-inflammatory, analgesic and antipyretic activities. The activity data of all compounds were listed and discussed in detail, among which some derivatives exhibited potent activities of particular interest.

2013 Elsevier Ltd. All rights reserved.

The amide bond exists widely in both natural and synthetic compounds. It is a core structure in pharmaceutical chemistry, being present in 25% of all synthetic drugs<sup>1</sup>. Partially, benzofuran-2-carboxamide derivatives are now known to possess extensive biological and medicinal activities such as anti-cancer,<sup>2-4</sup> anti-depression,<sup>5,6</sup> antimicrobial,<sup>7</sup> anti-hyperlipidemic,<sup>8,9</sup> nAChR agonist,<sup>10,11</sup> PtS inhibitor,<sup>12</sup> virus cell entry inhibitor,<sup>13</sup> Cathepsin K inhibitor<sup>14</sup> and MMP-13 inhibitor<sup>15</sup> activities. Even though, many synthetic approaches are reported to make these moieties, still there is a demand for new methods. Thus, the use of combinatorial approaches to the high-throughput synthesis of this drug-like scaffold would be a powerful advance in helping to speed up drug discovery.

On the other hand, microwave-assisted synthesis has become increasingly popular within the drug discovery due to their advantages of speed and convenience.<sup>16-19</sup> Comparing with the classic thermal transmission, microwave heating can effectively increase the rate of heating and chemical reaction. Furthermore, dedicated commercial microwave reactors have been developed for microwave-assisted parallel and combinatorial chemistry. A series of compounds can be prepared, sequentially in an automated single-mode instrument or in a parallel multimode instrument with multiple reactions.

Thus, using computer managed automatic microwave technology, synthesis of compound libraries for lead compounds including their screening and optimization can be achieved within very short span of time that required by classical thermal methods. In continuation to our previous efforts towards microwave assisted transformations,<sup>20,21</sup> we herein present a novel one-pot parallel approach via *O*-alkylation/Knoevenagel–condensation sequence under microwave conditions to obtain the library of benzofuran-2-carboxamide derivatives and their anti-inflammatory, analgesic and antipyretic activities in detail.



Scheme 1. Microwave assisted benzofuran-2-carboxamides in one hour

Generally, the carboxamide bond formation is typically mediated between carboxylic acid and amine by one of a myriad of coupling reagents, such as EDCI, DCC and CDI. However, the lack of diversity of commercial benzofuran-2-carboxylic acid brings a challenge to construct benzofuran-2-carboxamide library, because synthesis of these acid compounds must undergo a three-step two-pot or three-pot procedure that is time-consuming with low efficiency.<sup>22,23</sup> Our sequential studies on

<sup>\*</sup>Corresponding author: E-mail: dsshin@changwon.ac.kr

Phone: +82-55-213-3437, Fax: +82-55-213-3439

<sup>#</sup> Equally contributed

#### Tetrahedron Letters

Smiles rearrangement<sup>24</sup> for the synthesis of *N*-substituted anilines turned out to be a Knoevenagel condensation with 2acylphenols within an hour. This encouraged us to avoid difficulties mentioned above and to achieve efficient synthesis of benzofuran-2-carboxamide library. Thus, we've designed a novel microwave-assisted one-pot *O*-alkyalation/Knoevenagelcondensation reaction sequence. Preliminarily, 2-chloroacetyl amides were prepared by simple acetylation of amines with 2chloroacetyl chloride. Thereafter, the reaction between these amides and 2-acyl/formyl phenols afforded corresponding benzofuran-2-carboxamide under microwave irradiation in twostep one-pot manner involving *O*-alkylation of phenols followed by Knoevenagel type condensation as shown in Scheme 1.

As a model reaction, we first examined the reaction of 1-(5bromo-2-hydroxyphenyl)ethanone (1 equiv.) with 2chloroacetamide (1.2 equiv.) in DMF in the presence of different bases (2.5 equiv.). The reaction mixture was irradiated by microwave at 80 °C for 30 min followed at 145 °C for 30 min. After removing the solvent under reduced pressure, the residue was directly adsorbed on silica gel and purified by flash column chromatography (CombiFlash automatic, Teledyne, Inc.). Among all the bases used, Cs<sub>2</sub>CO<sub>3</sub> (45% yield) found to be better than K<sub>2</sub>CO<sub>3</sub> (35% yield) or Na<sub>2</sub>CO<sub>3</sub> (30% yield). By changing the solvent from DMF to CH<sub>3</sub>CN or addition of KI as catalyst along with all the above bases lead to drastic decrease in yields. Now, with the optimal reaction conditions in hand, the scope of microwave-assisted one-pot synthesis between 2-acyl phenols and 2-chloroacetyl amines was explored through a parallel approach and the yields of products (1-20) have been presented in Table 1.25 The structures of all synthesized benzofuran-2carboxamide derivatives were confirmed by NMR and HRMS analysis where the known compounds  $(1, 3-5 \text{ and } 8^{26a}, 9^{26a,b}, 6^{26c},$  $10^{26d,e}$  and  $12^{26f}$ ) are matched with the reported data. In addition, this method is faster and exploits the use of microwave over conventional heating processes which take more than 7 h for Knoevenagel condensation.<sup>26e</sup>

The two protons of NH<sub>2</sub> of N-unsubstituted benzofuran-2carboxamide derivatives (1-10) showed separate signals in the <sup>1</sup>H NMR. For example, <sup>1</sup>H NMR of compound 9 showed two protons of NH<sub>2</sub> exhibited different peaks. Only one chemical shift for amino proton was observed in <sup>1</sup>H NMR of Nmonosubstituted benzofuran-2-carboxamides (11-19). The products with low yields can be accounted by functional groups present either in amides or phenols, which affect the transformation. Even though, there is no big difference in the yields from all phenols, the ones with an electron withdrawing aryl group (2, 3 & 6) or an aldehyde at acyl subunit (9 and 10) gave comparatively low yields. A substitution on the nitrogen of chloroacetamides also made considerable decrease in the yields to obtain adducts. Aryl amides with electron withdrawing group on aryl group (11 and 16) gave moderate yields. The aryl amides with electron donating group (13, 17, 18 and 19) ended up with comparatively low yields may be due to mesomeric effects, which decreases the stability of carbanion in Knoevenagel condensation. A dibenzyl substituted chloroacetamide gave the corresponding product in good yields. The advantages over other synthetic methods involve short reaction periods, parallel synthesis, and moderate to good yields. After characterization, all the benzofuran-2-carboxamide derivatives were evaluated for their anti-inflammatory, analgesic and anti-pyretic activities at 50 mg/kg p.o.

 
 Table 1. Benzofuran-2-carboxamides from orthoacetylphenols and 2chloroacetamides.

Entry	2-Acyl/formylphenol	Chloroacetamide	Conditions <sup>a</sup>	Product Y	rield (%) <sup>t</sup>
1	о Іа он	CI NH2 IIa	2.5 equiv of Cs <sub>2</sub> CO <sub>3</sub> in DMF		75
2		CI NH <sub>2</sub> IIa	2.5 equiv of Cs <sub>2</sub> CO <sub>3</sub> in DMF	CI CI O 2 NH <sub>2</sub>	49
3	Br <b>k</b> OH O	CI NH2 IIa	2.5 equiv of Cs <sub>2</sub> CO <sub>3</sub> in DMF	Br O 3 NH <sub>2</sub>	45
4	Id OH	CI NH2 IIa	2.5 equiv of Cs <sub>2</sub> CO <sub>3</sub> in DMF	4 O NH2	59
5	Ph Ie OH	CI NH <sub>2</sub> IIa	2.5 equiv of Cs <sub>2</sub> CO <sub>3</sub> in DMF	$\overbrace{\overset{Ph}{}_{5^0}\overset{O}{}_{\mathrm{NH}_2}}^{\mathrm{Ph}}$	50
6	Cl ph If OH	CI NH <sub>2</sub> IIa	2.5 equiv of Cs <sub>2</sub> CO <sub>3</sub> in DMF	Cl Ph 6 NH <sub>2</sub>	74
7	O Ig OH	CI NH2 IIa	2.5 equiv of Cs <sub>2</sub> CO <sub>3</sub> in DMF		70
8	о фон	O CI IIa NH <sub>2</sub>	2.5 equiv of Cs <sub>2</sub> CO <sub>3</sub> in DMF		76
9	о н Бон о	CI NH <sub>2</sub> IIa	2.5 equiv of Cs <sub>2</sub> CO <sub>3</sub> in DMF		50
10	Ц ОН O	CI NH2 IIa	2.5 equiv of Cs <sub>2</sub> CO <sub>3</sub> in DMF		43
11	С Іа ОН О		2.5 equiv of Cs <sub>2</sub> CO <sub>3</sub> in DMF		57
12	La OH		2.5 equiv of Cs <sub>2</sub> CO <sub>3</sub> in DMF		55
13	O Ia OH O		2.5 equiv of Cs <sub>2</sub> CO <sub>3</sub> in DMF		Me 25
14			2.5 equiv of Cs <sub>2</sub> CO <sub>3</sub> in DMF		47
15	La OH		2.5 equiv of Cs <sub>2</sub> CO <sub>3</sub> in DMF		53
16	Ig OH OH	0 / /	2.5 equiv of Cs <sub>2</sub> CO <sub>3</sub> in DMF		43 1
17	Ia OH O		2.5 equiv of Cs <sub>2</sub> CO <sub>3</sub> in DMF		30
18	Ph Ig OH		2.5 equiv of Cs <sub>2</sub> CO <sub>3</sub> in DMF		30
19	Ie OH		2.5 equiv of Cs <sub>2</sub> CO <sub>3</sub> in DMF	Ph O 19 HN - N	40
20	O L Ia OH	Cl N.Bn IIg <sup>Bn</sup>	2.5 equiv of Cs <sub>2</sub> CO <sub>3</sub> in DMF	O O 20 Bn'	65

<sup>&</sup>lt;sup>a</sup>30 min (*t*) at 80 °C and further 30 min (*t*) at 145 °C. Reaction time (*t*) is the hold time after ramp time 10 min.

<sup>&</sup>lt;sup>b</sup>Yields refer to isolated pure compounds after column chromatography.

Entry	Anti-inflammatory activity Increase in paw volume ml $\pm$ SEM ( % inhibition of inflammation)				Analgesic activity % Increase in reaction time	Antipyretic activity % Reduction in rectal temperature
	1h	2h	3h	4h	60 min	5 h
Control	0.34±0.002	0.74±0.002	0.91±0.002	1.03±0.002	—	—
Diclofenac	0.25±0.010	0.27±0.011	0.25±0.016	0.27±0.001 (74)	_	—
Pentazocine				—	217	—
Paracetamol				—	_	74
1	0.35±0.009	0.77±0.017	$0.84 \pm 0.005$	1.00±0.013 (3)	2	5
2	0.37±0.007	0.72±0.005	$0.88 \pm 0.009$	1.00±0.007 (3)	1	6
3	0.30±0.005**	0.47±0.003**	0.76±0.007**	0.83±0.009** (19)	172	45
4	0.36±0.005	0.73±0.008	$0.85 \pm 0.007$	0.96±0.011 (7)	134	46
5	0.34±0.012	0.87±0.007	$0.86 \pm 0.009$	1.00±0.010 (3)	136	6
6	0.29±0.005	0.44±0.012	0.77±0.005	0.82±0.013 (20)	153	46
7	0.34±0.007	0.76±0.018	0.86±0.011	0.99±0.011 (4)	135	6
8	0.30±0.004	$0.46 \pm 0.007$	$0.77 \pm 0.005$	0.83±0.012 (19)	152	45
9	0.29±0.005**	0.36±0.007**	0.37±0.005**	0.36±0.009** (64)	160	64
10	0.38±0.003	0.85±0.015	0.89±0.003	1.00±0.008 (3)	134	7
11	0.29±0.007**	0.35±0.005**	0.37±0.002**	0.37±0.002** (64)	160	46
12	0.33±0.011	0.42±0.015	$0.44 \pm 0.005$	0.51±0.005 (50)	161	48
13	0.33±0.009**	0.38±0.007**	0.39±0.004**	0.39±0.005** (60)	167	49
14	0.29±0.009**	0.37±0.002**	0.38±0.003**	0.35±0.003** (66)	138	68
15	0.34±0.012	0.65±0.013	0.66±0.011	0.79±0.004 (23)	153	47
16	0.33±0.009**	0.38±0.005**	0.38±0.005**	0.38±0.005** (63)	160	45
17	0.30±0.005	0.42±0.005	0.71±0.002	0.80±0.002 (22)	169	63
18	0.33±0.005**	0.39±0.007**	0.38±0.003**	0.38±0.013** (63)	160	62
19	0.32±0.013**	0.34±0.007**	0.35±0.005**	0.37±0.002** (64)	160	60
20	0.33±0.009**	0.39±0.007**	0.39±0.007**	0.38±0.009** (63)	160	46

**Table 2.** Anti-inflammatory activity of benzofuran-2-carboxamide derivatives (**1-20**) by carrageenan induced rat paw edema method in rats, analgesic activity by tail flick method and antipyretic activity by brewer's yeast induced method.

SEM- standard error mean; n=6, \*p <0.05, \*\*p <0.01, \*\*\*p <0.001; -, not determined.

Anti-inflammatory activity was evaluated against carrageenan-induced paw edema method in Wistar rats.<sup>27</sup> The results are shown in Table 2. The standard drug diclofenac sodium was administered at dose of 20 mg/kg p.o. which gives 74% inhibition of inflammation at 4 h. Among the *N*-unsubstituted benzofuran-2-carboxamide derivatives, compound **9** showed good anti-inflammatory activity (65% inhibition) compared to other scaffolds. The methyl group at 5-position of benzofuran ring might be responsible for the anti-inflammatory activity.

In the *N*-substituted series, compounds **11**, **12**, **13**, **14**, **16**, **18**, **19** and **20** exhibited significant activity (50-66% inhibition) as compared to other compounds. The remaining benzofuran-2-carboxamide derivatives showed weak anti-inflammatory activity. Radiant heat tail-flick method in rats was used to screen the analgesic activity.<sup>28</sup> The effects of synthesized compounds and reference drug pentazocine (10 mg/kg i.p.) have been shown in Table 2 and expressed as percentage analgesia. Except compounds **1** and **2**, all the other synthesized compounds showed significant analgesia activity with 134-172% increase in reaction after 1 h treatment.

Furthermore, the antipyretic activity was evaluated against brewer's yeast induced method.<sup>29</sup> Paracetamol was used as standard drug at a dose of 150 mg/kg p.o. The percentage reduction in temperature after 5 h are summarized in Table 2,

indicates that the compounds **9**, **14**, **17** and **18** exhibit potent antipyretic activity causing more than 58% reduction in rectal temperature. The compounds **3**, **4**, **6**, **8**, **11**, **12**, **13**, **15**, **16**, **19** and **20** showed moderate activity (45-49%) as compared with other tested series.

In conclusion, a new series of benzofuran-2-carboxamide derivatives has been prepared by one pot microwave-assisted parallel synthesis that involves an *O*-alkylation followed by Knoevenagel condensation reaction sequence. All the compounds were fully characterized by spectral data. Most of the twenty synthesized compounds exhibited significant activities, among which, compound **9**, **11**, **14**, **18** and **19** showed best antiinflammatory, analgesic and anti-pyretic activities. This indicates that benzofuran-2-carboxamide derivatives can be considered as potential anti-inflammatory, analgesic and anti-pyretic agents. Further studies in relation to cytotoxicity and ADME are also warranted for the better understanding.

#### Acknowledgements

This work was supported by the grants from Ministry of Environment (KME, 412-111-008), National Research Foundation (NRF-2009-0094063) and Ministry of Knowledge Economy (MKE, R0000495), South Korea.

#### Supplementary data

#### CCEPTED ISCRIPT

#### Tetrahedron Letters

Detailed analytical data for all compounds and their biological activities have been provided in the supporting information.

References and notes

4

- 1 Ghose, A. K.; Viswanadhan, V. N.; Wendoloski, J. J. J. Comb. Chem. 1998, 1, 55-68.
- Choi, M.-J.; Jung, K. H.; Kim, D.; Lee, H.; Zheng, H.-M.; Park, B. H.; Hong, S.-W.; Kim, M.-H.; Hong, S.; Hong, S.-S. Cancer Lett. 2011. 306. 190-195.
- Parekh, S.; Bhavsar, D.; Savant, M.; Thakrar, S.; Bavishi, A.; 3. Parmar, M.; Vala, H.; Radadiya, A.; Pandya, N.; Serly, J.; Molnár, J.; Shah, A. Eur. J. Med. Chem. 2011, 46, 1942-1948.
- 4. Hranjec, M.; Sović, I.; Ratkaj, I.; Pavlović, G.; Ilić, N.; Valjalo, L.; Pavelić, K.; Kraljević Pavelić, S.; Karminski-Zamola, G. Eur. J. Med. Chem. 2013, 59, 111-119.
- Heinrich, T.; Böttcher, H.; Gericke, R.; Bartoszyk, G. D.; Anzali, S.; 5. Seyfried, C. A.; Greiner H. E.; van Amsterdam, C. J. Med. Chem. 2004, 47, 4684-4692.
- Dawson, L. A.; Watson, J. M. CNS Neurosci. Ther. 2009, 15, 107. 6.
- 7. Alper-Hayta, S.; Arisoy, M.; Temiz-Arpaci, O.; Yildiz, I.; Aki, E.; Özkan, S.; Kaynak, F. Eur. J. Med. Chem. 2008, 43, 2568–2578.
- 8 Shattat, G.; Al-Qirim, T.; Sweidan, K.; Shahwan, M.; El-Huneidi, W.; Al-Hiari, Y. J. Enzyme Inhib. Med. Chem. 2010, 25, 751-755.
- 9 Al-Qirim, T.; Shattat, G.; Sweidan, K.; El-Huneidi, W.; Sheikha, G. A.; Khalaf, S. Hikmat, R. A. Arch. Pharm. Chem. Life Sci. 2012, 345, 401-406.
- 10. Boess, F. G.; De Vry, J.; Erb, C.; Flessner, T.; Hendrix, M.; Luithle, J.; Methfessel, C.; Riedl, B.; Schnizler, K.; van der Staay, F.-J.; van Kampen, M.; Wiese, W. B.; Koenig, G. J. Pharmacol. Exp. Ther. 2007. 321. 716-725.
- 11. Mazurov, A. A.; Kombo, D. C.; Hauser, T. A.; Miao, L.; Dull, G.; Genus, J. F.; Fedorov, N. B.; Benson, L.; Sidach, S.; Xiao, Y.; Hammond, P. S.; James, J. W.; Miller, C. H.; Yohannes, D. J. Med. Chem. 2012, 55, 9793-9809.
- 12. Sledz, P.; Silvestre; H. L.; Hung, A.W.; Ciulli, A.; Blundell, T. L Abell, C. J. Am. Chem. Soc. 2010, 132, 4544-4545.
- Whitby, L. R.; Lee, A. M.; Kunz, S.; Oldstone, M. B. A.; Boger, D. 13. L. Bioorg. Med. Chem. Lett. 2009, 19, 3771-3774.
- 14. Yamashita, D. S.; Marquis, R. W.; Xie, R.; Nidamarthy, S. D.; Oh, H. J.; Jeong, J. U.; Erhard, K. F.; Ward, K.W.; Roethke, T. J.; Smith, B. R.; Cheng, H.Y.; Geng, X.; Lin, F.; Offen, P. H.; Wang, B.; Nevins, N.; Head, M. S.; Haltiwanger, R. C.; Sarjeant, A. A. N.; Sands, L. M. L.; Zhao, B.; Smith, W. W.; Janson, C. A.; Gao, E.; Tomaszek, T.; McQueney, M .; James, I. E.; Gress, C. J.; Zembryki, D. L.; Lark, M. W.; Veber, D. F. J. Med. Chem. 2006, 49, 1597-1612.
- 15. Chen, J. M.; Nelson, F. C.; Levin, J. I.; Mobilio, D.; Moy, F. J.; Nilakantan, R.; Zask, A.; Powers, R. J. Am. Chem. Soc. 2000, 122, 9648-9654
- 16. Shipe, W. D.; Wolkenberg, S. E.; Lindsley, C. W. Drug Discov. Today: Technol. 2005, 2, 155–161.
   Mavandadi, F.; Pilotti, Å. Drug Discov. Today 2006, 11, 165–174.
- 18. Alcázar, J.; Oehlrich, D. Future Med. Chem. 2010, 2, 169-176.
- Kappe, C. O.; Stadler, A.; Dallinger, D. Microwaves in Organic and Medicinal Chemistry, 2<sup>nd</sup> ed., Wiley-VCH Verlag GmbH & Co. 19. KGaA: Weinheim, Germany 2012.
- 20. Meng, L.-J.; Vijaykumar, B. V. D.; Zuo, H.; Li, Z.-B.; Gautam, D.; Jang, K.; Shin, D.-S. Tetrahedron: Asymmetry 2012, 23, 1029–1037.
- Meng, L.-J.; Zuo, H.; Vijaykumar, B. V. D.; Gautam, D.; Choi, K.-21. M.; Jang, K.; Yoon, Y.-J.; Shin, D.-S. Bull. Korean Chem. Soc. 2013, 34.585-589
- Kennis, L. E. J.; Bischoff, F. P.; Mertens, C. J., Love, C. J.; Van den Kevbus, F. A. F.: Pieters, S.: Braeken, M., Megens, A. A. H. P.: Leysen, J. E. Bioorg. Med. Chem. Lett. 2000, 10, 71-74.
- 23. Aboraia, A. S.; Yee, S. W.; Gomaa, M. S.; Shah, N.; Robotham, A. C.; Makowski, B.; Prosser, D.; Brancale, A.; Jones, G.; Simons, C. Bioorg. Med. Chem. 2010, 18, 4939-4946.
- 24. (a) Xie, Y.-S.; Vijaykumar, B. V. D.; Jang, K.; Shin, H.-H.; Zuo, H.; Shin, D.-S. Tetrahedron Lett. 2013, 54, 5151-5154. (b) Xie, Y.-S.; Vijaykumar, B. V. D.; Jang, K.; Choi, K.-M.; Zuo, H.; Yoon, Y.-J.; Shin, D.-S. Bull. Korean Chem. Soc. 2013, 34, 3881-3884.
- See supporting information for complete data. 25.
- (a) Rene, L.; Royer. R. Bull. Soc. Chim. Fr. 1971, 4329. (b) Lee, J.; Khanapure, S. P.; Kim, H.-O.; Rajur, R.; Li, B.; Williams, J. D.; Pai, R.; Peet, N. P. Synth. Commun. 2010, 40, 3390-3396. (c) Walker, G. N.; Smith, R. T. J. Org. Chem. 1971, 36, 305-308. (d) Bundesmann, M. W.; Coffey, S. B.; Wright, S. W. Tetrahedron Lett. 2010, 51,

3879-3882. (e) Bathe, A. US20100036139(A1), Feb. 11, 2010. (f) Marriott, K.-S. C.; Morrison, A. Z.; Moore, M.; Olubajo, O.; Stewart, L. E. Bioorg. Med. Chem. Lett. 2012, 20, 6856-6861.

- Winter, C. A.; Risely, E. A.; Nuss, G. W. Proc. Soc. Exp. Biol. Med. 1962. 111. 544-547.
- 28. D'Armour, F. E.; Smith, D. L. J. Pharmacol. Exp. Ther. 1941, 72, 74-79
- 29. Loux, J. J.; DePalma, P. D.; Yankell, S. L. Toxicol. Appl. Pharmcol. 1972, 22, 672-675.

-

#### **Graphical Abstract**

To create your abstract, type over the instructions in the template box below. Fonts or abstract dimensions should not be changed or altered.

